Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells. (Q53238656)

12 May 2018

title

Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells. (English)

1 reference

12 May 2018

author name string

Qu Cui

1

1 reference

12 May 2018

Hironobu Shibata

2

1 reference

12 May 2018

Asuka Oda

3

1 reference

12 May 2018

Hiroe Amou

4

1 reference

12 May 2018

Ayako Nakano

5

1 reference

12 May 2018

Kenichiro Yata

6

1 reference

12 May 2018

Masahiro Hiasa

7

1 reference

12 May 2018

Keiichiro Watanabe

8

1 reference

12 May 2018

Shingen Nakamura

9

1 reference

12 May 2018

Hirokazu Miki

10

1 reference

12 May 2018

Takeshi Harada

11

1 reference

12 May 2018

Shiro Fujii

12

1 reference

12 May 2018

Kumiko Kagawa

13

1 reference

12 May 2018

Kyoko Takeuchi

14

1 reference

12 May 2018

Shuji Ozaki

15

1 reference

12 May 2018

Toshio Matsumoto

16

1 reference

12 May 2018

Masahiro Abe

17

1 reference

12 May 2018

publication date

23 June 2011

1 reference

12 May 2018

International Journal of Hematology

published in

1 reference

12 May 2018

volume

94

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

63-70

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1007/s12185-011-0885-9

exact match

0 references

cites work

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Advances in the understanding of myeloma bone disease and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Gammadelta T cells and the lymphoid stress-surveillance response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Essential contribution of germline-encoded lysine residues in Jgamma1.2 segment to the recognition of nonpeptide antigens by human gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Analysis of mechanism for human gammadelta T cell recognition of nonpeptide antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

V gamma 9V delta 2 T cell response to colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0885-9

Generating Human Osteoclasts from Peripheral Blood

21 January 2018

1 reference

12 December 2020

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells

1 reference

12 December 2020

Professional antigen-presentation function by human gammadelta T Cells

1 reference

12 December 2020

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma

1 reference

12 December 2020

BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

1 reference

12 December 2020

Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

1 reference

12 December 2020

10.1007/S12185-011-0885-9

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

21698356

1 reference

12 May 2018